Isoform-specific contribution of protein kinase C to prion processing

Molecular and Cellular Neuroscience

Volumn 39, Issue 3, 2008, Pages 400-410

  Alfa Cissé, Moustapha ^a   Louis, Krystel ^b   Braun, Uschi ^c   Mari, Bernard ^a   Leitges, Michael ^c   Slack, Barbara E ^d   Fisher, Abraham ^e   Auberger, Patrick ^f   Checler, Frédéric ^a   Vincent, Bruno ^a  

^a CNRS   (France)

^b CHU SART TILMAN   (Belgium)

^c UNIVERSITY OF OSLO   (Norway)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

^f INSERM   (France)

Author keywords

secretase; Disintegrins; N1 fragment; PKC; PrPc; Regulation

Indexed keywords

CELLULAR PRION PROTEIN; MUSCARINIC RECEPTOR; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; THREONINE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; FIBROBLAST; FLUOROMETRY; HUMAN; MUTATION; PHOSPHORYLATION; PRION DISEASE; PRIORITY JOURNAL; STIMULATION;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CARBACHOL; CELL LINE; CHOLINERGIC AGONISTS; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITORS; FIBROBLASTS; HUMANS; INDOLES; ISOENZYMES; MALEIMIDES; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PHORBOL ESTERS; PROTEIN KINASE C; PRPC PROTEINS;

EID: 53849113627     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcn.2008.07.013     Document Type: Article

References (40)

1. Aguzzi A., and Polymenidou M. Mammalian prion biology: one century of evolving concepts. Cell 116 (2004) 1-20
2. Alfa Cissé M., Sunyach C., Lefranc-Jullien S., Postina R., Vincent B., and Checler F. The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity. J. Biol. Chem. 281 (2005) 40624-40631
3. Alfa Cissé M., Gandreuil C., Hernandez J.F., Martinez J., Checler F., and Vincent B. Design and characterization of a novel cellular prion-derived quenched fluorimetric substrate of α-secretase. Biochem. Biophys. Res. Commun. 347 (2006) 254-260
4. Alfa Cissé M., Sunyach C., Slack B.E., Fisher A., Vincent B., and Checler F. M1 and M3 muscarinic receptors control physiological processing of cellular prion protein by modulating ADAM17 phosphorylation and activity. J. Neurosci 27 (2007) 4083-4092
5. Ancolio K., Dumanchin C., Barelli H., Warter J.M., Brice A., Campion D., Frébourg T., and Checler F. Unusual phenotypic alteration of β amyloid precursor protein (βAPP) maturation by a new Val-715/Met βAPP-770 mutation responsible for probable early-onset Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 4119-4124
6. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-259
7. Büeler H., Fischer M., Lang Y., Bluethmann H., Lipp H., DeArmond S., Prusiner S.B., Aguet M., and Weissmann C. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356 (1992) 577-582
8. Büeler H., Aguzzi A., Sailer A., Greiner R., Autenried P., Aguet M., and Weissmann C. Mice devoid of PrP are resistant to scrapie. Cell 73 (1993) 1339-1347
9. Caccamo A., Oddo S., Billings L.M., Green K.N., Martinez-Coria H., Fisher A., and La Ferla F.M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49 (2006) 671-682
10. Cashman N.R., Loertscher R., Nalbantoglu J., Shaw I., Kascsak R.J., Bolton D.C., and Bendheim P.E. Cellular isoform of the scrapie agent protein participates in lymphocyte activation. Cell 61 (1990) 185-192
11. Chen S.G., Teplow D.B., Parchi P., Teller J.K., Gambetti P., and Autilio-Gambetti L. Truncated forms of the human prion protein in normal brain and prion diseases. J. Biol. Chem. 270 (1995) 19173-19180
12. Collazos A., Diouf B., Guérineau N., Quittau-Prévostel C., Peter M., Coudane F., Hollande F., and Joubert D. A spatiotemporally coordinated cascade of protein kinase C activation controls isoform-selective translocation. Mol. Cell. Biol. 26 (2006) 2247-2261
13. Collinge J., Whittington M.A., Sidle K.C.L., Smith C.J., Palmer M.S., Clarke A.R., and Jefferys J.G.R. Prion protein is necessary for normal synaptic function. Nature 370 (1994) 295-297
14. Demart S., Fournier J.G., Cremignon C., Frobert J., Lamoury F., Marce D., Lasmézas C., Dormont D., Grassi J., and Deslys J.P. New insight into abnormal prion protein using monoclonal antibodies. Biochem. Cell Biol. 265 (1999) 652-657
15. Etcheberrigaray R., Tan M., Dewachter I., Kuipéri C., Van der Auwera I., Wera S., Qiao L., Bank B., Nelson T.J., Kozikowski A.P., Van Leuven F., and Alkon D.L. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 11141-11146
16. Ettaiche M., Pichot R., Vincent J.P., and Chabry J. In vivo cytotoxicity of the prion protein fragment 106-126. J. Biol. Chem. 275 (2000) 36487-36490
17. Felder C.C. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J. 9 (1995) 619-625
18. Forloni G., Angeretti N., Chiesa R., Monzani E., Salmona M., Bugiani O., and Tagliavini F. Neurotoxicity of a prion protein fragment. Nature 362 (1993) 543-546
19. Kinouchi T., Sorimachi H., Maruyama K., Mizuno K., Ohno S., Ishiura S., and Suzuki K. Conventional protein kinase C (PKC)-α and novel PKCε, but not δ, increase the secretion of an N-terminal fragment of Alzheimer's disease amyloid precursor protein from PKC cDNA transfected 3Y1 cells. FEBS Lett. 364 (1995) 203-206
20. Laffont-Proust I., Faucheux B.A., Hässig R., Sazdovitch V., Simon S., Grassi J., Hauw J.J., Moya K.L., and Haïk S. The N-terminal cleavage of cellular prion protein in the human brain. FEBS Lett. 579 (2005) 6333-6337
21. Louis K., Guérineau N., Fromigue O., Defamie V., Collazos A., Anglard P., Shipp M.A., Auberger P., Joubert D., and Mari B. Tumor cell-mediated induction of the stromal factor stromelysin-3 requires heterotypic cell contact-dependent activation of specific protein kinase C isoforms. J. Biol. Chem. 280 (2005) 1272-1283
22. Marano C.W., Laughlin K.V., Russo L.M., and Mullin J.M. The protein kinase C inhibitor, bisindolylmaleimide, inhibits the TPA-induced but not the TNF-induced increase in LLC-PK1 transepithelial permeability. Biochem. Biophys. Res. Commun. 209 (1995) 669-676
23. Mellor H., and Parker P.J. The extended protein kinase C superfamily. Biochem. J. 332 (1998) 281-292
24. Middlehoven P.J., Ager A., Roos D., and Verhoeven A.J. Involvement of a metalloprotease in the shedding of human neutrophil FcgRIIIB. FEBS Lett. 414 (1997) 14-18
25. Mouillet-Richard S., Ermonval M., Chebassier C., Laplanche J.L., Lehmann S., Launay J.M., and Kellermann O. Signal transduction through prion protein. Science 289 (2000) 1925-1928
26. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334 (1988) 661-665
27. Nitsch R.M., Slack B.E., Wurtman R.J., and Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258 (1992) 304-307
28. Paitel E., Sunyach C., Alves da Costa C., Bourdon J.C., Vincent B., and Checler F. Primary cultured neurons devoid of cellular prion display lower responsiveness to staurosporine through the control of p53 at both transcriptional and post-transcriptional levels. J. Biol. Chem. 279 (2004) 612-618
29. Poole A.W., Pula G., Hers I., Crosby D., and Jones M.L. PKC-interacting proteins: from function to pharmacology. Trends in Pharm. Sci. 25 (2004) 529-535
30. Prusiner S.B. Prions. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 13363-13383
31. Rieger R., Edenhofer F., Lasmezas C.I., and Weiss S. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukacyotic cells. Nat. Med. 3 (1997) 1383-1388
32. Romanova L.Y., Alexandrov I.A., Nordan R.P., Blagosklonny M.V., and Mushinski J.F. Cross-talk between protein kinase C-alpha (PKC-alpha) and -delta (PKC-delta): PKC-alpha elevates the PKC-delta protein level, altering its mRNA transcription and degradation. Biochemistry U.S.A. 37 (1998) 5558-5565
33. Rybin V.O., Sabri A., Short J., Braz J.C., Molkentin J.D., and Steinberg S.F. Cross-regulation of novel protein kinase C (PKC) isoform function in cardiomyocytes. Role of PKC epsilon in activation loop phosphorylations and PKC delta in hydrophobic motif phosphorylations. J. Biol. Chem. 278 (2003) 14555-14564
34. Sunyach C., Alfa Cissé M., Alves da Costa C., Vincent B., and Checler F. The C-terminal products of cellular prion protein processing, C1 and C2, exert distinct influence on p53-dependent staurosporine-induced caspase-3 activation. J. Biol. Chem. 282 (2007) 1956-1963
35. Tobler I., Gaus S.E., Deboer T., Achermann P., Fisher M., Rülicke T., Moser M., Oesch B., McBride P.A., and Manson J.C. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature 380 (1996) 639-642
36. Toullec D., Pianetti P., Coste H., Bellevergue P., Grand-Perret T., Ajakane M., Baudet V., Boissin P., Boursier E., and Loriolle F. The bisindolethylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266 (1991) 15771-15781
37. Vilette D., Andreoletti O., Archer F., Madeleine M.F., Vilotte J.L., Lehmann S., and Laude H. Ex vivo propagation of infectious sheep scrapie agent in heterologous epithelial cells expressing ovine prion protein. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 4055-4059
38. Vincent B., Paitel E., Frobert Y., Lehmann S., Grassi J., and Checler F. Phorbol esters-regulated cleavage of normal prion protein in HEK293 human cells and murine neurons. J. Biol. Chem. 275 (2000) 35612-35616
39. Vincent B., Paitel E., Saftig P., Frobert Y., Hartmann D., de Strooper B., Grassi J., Lopez-Perez E., and Checler F. The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. J. Biol. Chem. 276 (2001) 37743-37746
40. Zhang Y., Jiang J., Black R.A., Baumann G., and Franck S.J. Tumor necrosis factor-α converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADM17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation. Endocrinology 141 (2000) 4342-4348